Orylnvah is a broad-spectrum oral penem antibiotic for women who have limited or no alternative treatment options, according to an Oct. 24 FDA news release.
In trials, Orylnvah had a 62% composite response rate, compared to 55% composite response rate in patients treated with amoxicillin/clavulanate. It also was found to be superior to ciprofloxacin, with a 48% composite response rate compared to 33% in the ciprofloxacin group.
The most common side effects were diarrhea, nausea, vaginal yeast infection, headache and vomiting, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.